<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087747</url>
  </required_header>
  <id_info>
    <org_study_id>AChol</org_study_id>
    <nct_id>NCT03087747</nct_id>
  </id_info>
  <brief_title>Percutaneous Transhepatic Cholangiography (PTHC) in Acute Cholecystitis and Clinical Outcomes</brief_title>
  <official_title>Percutaneous Drainage in a Setting of Acute Cholecystitis Severity Grade III and Correlation With Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Split, School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Split, School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a setting of acute cholecystitis (AC) one of the treatment option is percutaneous&#xD;
      transhepatic cholangiography (PTHC) drainage. The goal of current study is to evaluate some&#xD;
      radiology aspects and correlate with clinical patient outcomes in patients with acute&#xD;
      cholecystitis severity grade III (presented as acute cholecystitis with organ dysfunction).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Up to 8 weeks.</time_frame>
    <description>C-reactive protein (CRP) is a protein found in blood plasma, whose levels rise in response to inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drainage duration (expressed in days)</measure>
    <time_frame>Up to 16 weeks.</time_frame>
    <description>The drain which is placed in gallbladder during Percutaneous transhepatic cholangiography (PTHC) remains there until resolving clinical parameters of acute cholecystitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cells (WBCs) count</measure>
    <time_frame>Up to 8 weeks.</time_frame>
    <description>White blood cells (WBCs) are the cells of the immune system. During inflammation White blood cell level rise.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Cholecystitis, Acute</condition>
  <condition>Elderly Infection</condition>
  <condition>Drain Abscess</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous cholecystostomy</intervention_name>
    <description>Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute cholecystitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical markers of acute cholecystitis&#xD;
&#xD;
          -  diagnosis confirmed with some imaging technique: computed tomography (CT), ultrasound&#xD;
             (US).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis was not confirmed with imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Liana Cambj Sapunar, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Split</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Split, School of Medicine</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Split, School of Medicine</investigator_affiliation>
    <investigator_full_name>Marija Cavar</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

